Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.
EP. 1: Case Overview: Castrate-Sensitive Prostate Cancer
An overview of the diagnostic work-up and treatment options offered to a 76-year-old male with castrate-sensitive prostate cancer who experiences recurrence.
EP. 2: Managing Castrate-Sensitive Prostate Cancer
Important considerations for oncologists who manage prostate cancer when establishing a treatment plan for a patient with castrate-sensitive disease.
EP. 3: Castrate-Sensitive Prostate Cancer: Frontline Therapy
Current treatment options available to treat hormone-sensitive prostate cancer in the first-line setting and factors that impact treatment selection.
EP. 4: Castrate-Sensitive Prostate Cancer: Treatment Planning
The importance of risk stratifying patients with hormone-sensitive prostate cancer, and recommendations for germline and somatic testing.
EP. 5: Castrate-Sensitive Prostate Cancer: Second-Line Therapy
Second-line therapies available to treat hormone-sensitive prostate cancer and recommendations for use based on current clinical data.
EP. 6: Castrate-Sensitive Prostate Cancer: Monitoring Response to Therapy
Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.
EP. 7: Castrate-Sensitive Prostate Cancer: TITAN Trial Outcomes
An overview of the phase 3 TITAN trial in castrate-sensitive prostate cancer and implications for treating appropriate patients with apalutamide and androgen deprivation therapy.
EP. 8: Treatment Advances in Castrate-Sensitive Prostate Cancer
Nicholas Vogelzang, MD, FASCO, FACP, reacts to treatment advances in hormone-sensitive prostate cancer and provides advice to oncologists who work in community settings on best practices for managing these patients using newer treatment strategies.
2 Clarke Drive Cranbury, NJ 08512